Skip to contentpdufa.bio

OPGx-BEST1 Phase

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

OPGx-BEST1 Phase is an Opus Genetics, Inc. program in BEST1-related retinal disease (BVMD, ARB). Its next catalyst is a Readout in Q1 2027.

IRD catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: BEST1-related retinal disease (BVMD, ARB). Sponsor: Opus Genetics, Inc. (IRD). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q1 2027IRD

Specialist biotech funds holding IRD, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Perceptive Advisors9,000,000$43.6 millionfiled November 16, 2026
Cormorant Asset Management5,500,000$26.6 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is OPGx-BEST1 Phase's next FDA decision or readout?

The next tracked catalyst for OPGx-BEST1 Phase is a Readout in Q1 2027.

What happened at OPGx-BEST1 Phase's most recent FDA decision?

No FDA decision for OPGx-BEST1 Phase is in our archive yet.

What is OPGx-BEST1 Phase used for?

In our records OPGx-BEST1 Phase is under review or in development for BEST1-related retinal disease (BVMD, ARB).

Who makes OPGx-BEST1 Phase?

Opus Genetics, Inc. (IRD).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.